Table 3.
Clinical and laboratory parameters of COVID‐19 patients before and after TZC treatment
| Case No. | Before TCZ therapy | Day of TCZ therapy | Days after TCZ therapy | Clinical outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day of hospitalization | Day of ICU admission | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 10 | ||||
| Ventilation and oxygenation | |||||||||||||
| 1 | Time vs TCZ | 2 d prior | Same day | Discharged home d 10 post‐TCZ. | |||||||||
| O2 delivery method | ETT | ETT | ETT | ETT | ETT | NP | NP | NP | RA | RA | RA | ||
| FiO2 (%) | 80 | 30 | 30 | 30 | 35 | 36 | 36 | 28 | 21 | 21 | 21 | ||
| PF ratio (mm Hg) | 124 | 253 | 253 | 253 | 209 | 226 | 306 | 286 | |||||
| 2 | Time vs TCZ | 8 d prior | Same day | Discharged home d 13 post‐TCZ. | |||||||||
| O2 delivery method | RA | HM | HM | NP | NP | NP | NP | NP | NP | NP | RA | ||
| FiO2 (%) | 21 | 60 | 60 | 36 | 36 | 36 | 36 | 32 | 28 | 28 | 21 | ||
| PF ratio (mm Hg) | 198 | 198 | 277 | ||||||||||
| 3 | Time vs TCZ | Same day | Same day | D 19 post‐TCZ: remains in hospital on ward bed on oxygen 2 L/min. | |||||||||
| O2 delivery method | HM | HM | HM | NP | NP | NP | NP | NP | NP | NP | NP | ||
| FiO2 (%) | 60 | 60 | 60 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 28 | ||
| PF ratio (mm Hg) | 93 | 93 | 93 | 277 | |||||||||
| 4 | Time vs TCZ | 7 d prior | 6 d prior | D 26 post‐TCZ: remains in hospital on ward bed on oxygen 2 L/min. | |||||||||
| O2 delivery method | RA | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ||
| FiO2 (%) | 21 | 45 | 55 | 60 | 70 | 60 | 40 | 40 | 30 | 40 | 40 | ||
| PF ratio (mm Hg) | 342 | 112 | 97 | 81 | 95 | 165 | 135 | 186 | 140 | 165 | |||
| 5 | Time vs TCZ | 6 d prior | 2 d prior | D 24 post‐TCZ: remains in hospital on ward bed, breathing room air, on renal dialysis. | |||||||||
| O2 delivery method | RA | HM | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ETT | ||
| FiO2 (%) | RA | 30 | 100 | 45 | 50 | 35 | 35 | 35 | 30 | 35 | 30 | ||
| PF ratio (mm Hg) | 183 | 69 | 193 | 128 | 314 | 197 | 171 | 213 | 200 | 267 | |||
| CRP (mg/L; NR ≤ 4.9) | |||||||||||||
| 1 | 227 | 236 | 236 | 216 | 86 | 33 | 16 | 4 | 3 | ||||
| 2 | 82 | 128 | 128 | 37 | 17 | 12 | 9 | 6 | |||||
| 3 | 269 | 269 | 269 | 236 | 86 | 40 | 21 | 11 | 7 | 2 | |||
| 4 | 91 | 226 | 530 | 389 | 164 | 73 | 40 | 24 | 17 | 17 | 12 | ||
| 5 | 87 | 105 | 312 | 319 | 177 | 89 | 23 | 6 | 3 | ||||
| Ferritin (μg/L; NR 30‐400) | |||||||||||||
| 1 | 4700 | 4396 | 4396 | 4501 | 2684 | 2670 | |||||||
| 2 | 259 | 738 | 738 | 545 | 470 | 379 | 457 | 420 | 420 | ||||
| 3 | 731 | 731 | 731 | 774 | 865 | 812 | 762 | 681 | 669 | 546 | |||
| 4 | 3177 | 2666 | 2296 | ||||||||||
| 5 | 2080 | 2074 | 1611 | 1501 | |||||||||
| LDH (U/L; NR ≤ 250) | |||||||||||||
| 1 | 471 | 362 | 362 | 466 | 288 | 394 | |||||||
| 2 | 255 | 255 | 213 | 221 | 227 | 231 | 202 | ||||||
| 3 | 731 | 731 | 417 | 309 | 328 | 281 | 254 | 291 | 230 | 270 | |||
| 4 | 324 | 303 | 280 | ||||||||||
| 5 | 705 | 541 | |||||||||||
Abbreviations: COVID‐19, coronavirus disease 2019; CRP, C‐reactive protein; ETT, endotracheal tube; FiO2, fraction of inspired oxygen; HM, Hudson mask; ICU, intensive care; LDH, lactate dehydrogenase; NP, nasal prongs; NR, normal range; O2, oxygen; PF ratio, ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen; RA, room air; TCZ, tocilizumab; U/L, units per liter.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.